Bharat Biotech International Limited

bharatbiotech.com

Bharat Biotech International Limited is a multidimensional biotechnology company specializing in product-oriented research and development leading to the manufacture of vaccines and biotherapeutics. Bharat Biotech was established in the year 1996 by Dr. Krishna M. Ella and Mrs. Suchitra K. Ella.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

INRAE, EVOLUGATE ENTER OPTION LICENSE AGREEMENT TO ADVANCE PROBIOTICS TO MANAGE HUMAN CHOLESTEROL

Evolugate | May 28, 2020

news image

INRAE, is pleased to announce that it has entered into an exclusive option license agreement with biotechnology company Evolugate of Gainesville, FL to optimize its probiotic to manage human hypercholesterolemia, a major risk factor for cardiovascular diseases.INRAE is the first worldwide research institute in agronomy. INRAE-Micalis has been investigating the human microbiome to identify microbes that can influence hypercholesterolemia. They have selected microbes that degrade or sequeste...

Read More

CELL AND GENE THERAPY

RAPID RESHORE & DEVELOPMENT AND BRAINSTORM CELL THERAPEUTICS ANNOUNCE AGREEMENT TO ADVANCE CONSTRUCTION OF BRAINSTORM'S U.S. MANUFACTURING FACILIT

BrainStorm Cell Therapeutics | October 26, 2020

news image

Rapid Reshore & Development (RR&D), an alliance of three specialized firms, and BrainStorm Cell Therapeutics, Inc (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced that BrainStorm has selected RR&D as its partner to expedite site selection and design services for a state-of-the-art manufacturing facility for NurOwn® (autologous MSC-NTF) in the U.S. BrainStorm is investigating NurOwn as a potential treatment for neurodegener...

Read More

CELL AND GENE THERAPY, INDUSTRIAL IMPACT

CBM ANNOUNCES PARTNERSHIP WITH VIRION THERAPEUTICS

Center for Breakthrough Medicines | February 27, 2023

news image

Center for Breakthrough Medicines (CBM), a leading contract development and manufacturing organization dedicated to addressing the challenges of commercializing cell and gene therapies, and Virion Therapeutics, a clinical-stage biotech firm focused on developing accessible and adaptable CD8+ T cell-based technologies for cancer and infectious diseases, have recently announced a strategic collaboration agreement. CBM will partner and manufacture with Virion Therapeutics on their ...

Read More

INDUSTRIAL IMPACT

IPA’S SUBSIDIARY BIOSTRAND AND BRIACELL ANNOUNCE ARTIFICIAL INTELLIGENCE COLLABORATION AND LICENSE AGREEMENT

BriaCell Therapeutics Corp. | December 01, 2022

news image

IPA an advanced biotherapeutic research and technology company, announced that BioStrand BV an AI in silico discovery subsidiary of IPA, has entered into a research collaboration and license agreement with BriaCell Therapeutics Corp. a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer. The collaboration will leverage BioStrand’s LENSai™ software, built upon IPA’s proprietary HYFT™ Universal Fingerprint™ technolog...

Read More
news image

INRAE, EVOLUGATE ENTER OPTION LICENSE AGREEMENT TO ADVANCE PROBIOTICS TO MANAGE HUMAN CHOLESTEROL

Evolugate | May 28, 2020

INRAE, is pleased to announce that it has entered into an exclusive option license agreement with biotechnology company Evolugate of Gainesville, FL to optimize its probiotic to manage human hypercholesterolemia, a major risk factor for cardiovascular diseases.INRAE is the first worldwide research institute in agronomy. INRAE-Micalis has been investigating the human microbiome to identify microbes that can influence hypercholesterolemia. They have selected microbes that degrade or sequeste...

Read More
news image

CELL AND GENE THERAPY

RAPID RESHORE & DEVELOPMENT AND BRAINSTORM CELL THERAPEUTICS ANNOUNCE AGREEMENT TO ADVANCE CONSTRUCTION OF BRAINSTORM'S U.S. MANUFACTURING FACILIT

BrainStorm Cell Therapeutics | October 26, 2020

Rapid Reshore & Development (RR&D), an alliance of three specialized firms, and BrainStorm Cell Therapeutics, Inc (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced that BrainStorm has selected RR&D as its partner to expedite site selection and design services for a state-of-the-art manufacturing facility for NurOwn® (autologous MSC-NTF) in the U.S. BrainStorm is investigating NurOwn as a potential treatment for neurodegener...

Read More
news image

CELL AND GENE THERAPY, INDUSTRIAL IMPACT

CBM ANNOUNCES PARTNERSHIP WITH VIRION THERAPEUTICS

Center for Breakthrough Medicines | February 27, 2023

Center for Breakthrough Medicines (CBM), a leading contract development and manufacturing organization dedicated to addressing the challenges of commercializing cell and gene therapies, and Virion Therapeutics, a clinical-stage biotech firm focused on developing accessible and adaptable CD8+ T cell-based technologies for cancer and infectious diseases, have recently announced a strategic collaboration agreement. CBM will partner and manufacture with Virion Therapeutics on their ...

Read More
news image

INDUSTRIAL IMPACT

IPA’S SUBSIDIARY BIOSTRAND AND BRIACELL ANNOUNCE ARTIFICIAL INTELLIGENCE COLLABORATION AND LICENSE AGREEMENT

BriaCell Therapeutics Corp. | December 01, 2022

IPA an advanced biotherapeutic research and technology company, announced that BioStrand BV an AI in silico discovery subsidiary of IPA, has entered into a research collaboration and license agreement with BriaCell Therapeutics Corp. a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer. The collaboration will leverage BioStrand’s LENSai™ software, built upon IPA’s proprietary HYFT™ Universal Fingerprint™ technolog...

Read More